

Consolidated Profit & Loss Account For Continuing Operations

	1 st Quarter 2001 \$m	1 st Quarter 2000 \$m
Sales	3,991	3,892
Cost of sales	(1,074)	(1,072)
Distribution costs	(30)	(63)
Research and development	(672)	(597)
Selling, general and administrative expenses	(1,321)	(1,218)
Other operating income	161	34
Operating profit before exceptional items	1,055	976
Exceptional items charged to operating profit	(25)	(83)
Operating profit	1,030	893
Share of joint ventures' and associates' operating profits	-	22
Profit on sale of fixed assets	10	-
Net interest and dividend income	55	19
Profit on ordinary activities before taxation	1,095	934
Profit before taxation before exceptional items	1,110	1,017
Exceptional items charged to profit before taxation	(15)	(83)
Taxation	(310)	(270)
Profit on ordinary activities after taxation	785	664
Attributable to minorities	(3)	(2)
Net profit for the period	782	662
Earnings per Ordinary Share before exceptional items	\$0.45	\$0.41
Earnings per Ordinary Share	\$0.44	\$0.38
Diluted earnings per Ordinary Share	\$0.44	\$0.38
Weighted average number of Ordinary Shares in issue (millions)	1,766	1,773
Diluted average number of Ordinary Shares in issue (millions)	1,768	1,776

Consolidated Balance Sheet

	31 Mar 2001 \$m	31 Dec 2000 \$m
Fixed assets	7,650	7,919
Current assets	11,036	10,515
Total assets	18,686	18,434
Creditors due within one year	(6,994)	(6,897)
Net current assets	4,042	3,618
Total assets less current liabilities	11,692	11,537
Creditors due after more than one year	(903)	(927)
Provisions for liabilities and charges	(1,124)	(1,068)
Net assets	9,665	9,542
Capital and reserves		
Shareholders' funds and minority interests	9,665	9,542

Consolidated Cash Flow Statement

	1st Quarter 2001 \$m	1st Quarter 2000 \$m
Cash flow from operating activities		
Operating profit before exceptional items	1,055	1,077
Depreciation and amortisation	212	261
Decrease/(increase) in working capital and other non-cash movements	110	(417)
Net cash inflow from operating activities before exceptional items	1,377	921
Outflow related to exceptional items	(105)	(287)
Net cash inflow from operating activities	1,272	634
Returns on investments and servicing of finance	58	53
Tax paid	(86)	(60)
Capital expenditure and financial investment	(345)	(295)
Acquisitions and disposals	(20)	-
Net cash inflow before management of liquid resources and financing	879	332
Net (purchase)/issues of shares	(126)	(166)
Exchange and other movements	(42)	17
Increase in net cash funds in the period	711	183
Net cash funds at beginning of period	3,605	2,169
Net cash funds at end of period	4,316	2,352

Notes to the Interim Financial Statements

1 BASIS OF PREPARATION AND ACCOUNTING POLICIES

The results for the quarter ended 31 March 2001 have been prepared in accordance with UK generally accepted accounting principles. The accounting policies applied are those set out in AstraZeneca PLC's 2000 Annual Report and Form 20-F. In 2001, the continued standardisation of accounting treatments across AstraZeneca has led certain subsidiaries to classify as cost of sales some elements of expense recorded as distribution costs in previous periods. The effect of this change in the current period is to reclassify approximately \$30m of costs. These interim financial statements do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2000 will be filed with the Registrar of Companies following the Company's Annual General Meeting. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

2 TERRITORIAL SALES ANALYSIS

	1 st Quarter 2001 \$m	1 st Quarter 2000 \$m	% Growth	
			Actual	Constant Currency
USA	2,139	2,021	6	6
Japan	178	156	14	26
France	238	231	3	13
Germany	168	175	(4)	5
Italy	150	153	(2)	9
Sweden	67	87	(23)	(15)
UK	172	184	(7)	-
Rest of World	879	885	(1)	10
Total	3,991	3,892	3	7

3 PRODUCT SALES ANALYSIS

	1 st Quarter 2001 \$m	1 st Quarter 2000 \$m	% Growth	
			Actual	Constant Currency
Gastrointestinal:				
Losec	1,495	1,588	(6)	(3)
Nexium	81	-	n/m	n/m
Others	12	11	9	9
Total Gastrointestinal	1,588	1,599	(1)	2
Cardiovascular:				
Zestril	294	276	7	11
Seloken	151	106	42	49
Plendil	106	115	(8)	(3)
Tenormin	98	119	(18)	(11)
Atacand	83	56	48	59
Imdur	21	23	(9)	-
Others	82	99	(17)	(9)
Total Cardiovascular	835	794	5	11

3 PRODUCT SALES ANALYSIS CONT.

	1 st Quarter 2001 \$m	1 st Quarter 2000 \$m	% Growth	
			Actual	Constant Currency
Respiratory:				
Pulmicort	200	174	15	22
Rhinocort	56	41	37	42
Accolate	49	55	(11)	(9)
Oxis	32	27	19	30
Bricanyl	28	34	(18)	(9)
Symbicort	3	-	n/m	n/m
Others	13	14	(7)	7
Total Respiratory	381	345	11	18
Oncology:				
Zoladex	160	167	(4)	3
Nolvadex	139	139	-	3
Casodex	115	115	-	5
Arimidex	43	37	16	24
Others	7	7	-	-
Total Oncology	464	465	-	5
CNS:				
Seroquel	189	82	130	132
Zomig	66	65	2	5
Other CNS	2	8	n/m	n/m
Total CNS	257	155	66	69
Pain, Infection and Other Pharma:				
Diprivan	107	164	(35)	(31)
Merrem	49	36	36	44
Xylocaine	47	54	(13)	(7)
Marcaine	19	21	(10)	(5)
Naropin	15	13	15	23
Other Pharma Products	127	142	(11)	(7)
Total Pain, Infection and Other Pharma	364	430	(15)	(10)
Salick Health Care	45	45	-	-
Astra Tech	30	28	7	18
Marlow Foods	27	25	8	20
Other	-	6	n/m	n/m
	102	104	(2)	4
Total	3,991	3,892	3	7

n/m not meaningful

Shareholder Information

ANNOUNCEMENTS AND MEETINGS

Annual General Meeting	26 April 2001
Announcement of half year results	26 July 2001
Announcement of third quarter and nine month results	24 October 2001

DIVIDENDS

The record date for the second interim dividend payable on 9 April 2001 (in the UK, Sweden and the US) was 23 February 2001. Ordinary Shares traded ex-dividend on the London and Stockholm Stock Exchange from 21 February 2001. ADSs traded ex-dividend on the New York Stock Exchange from the same date.

Future dividends will normally be paid as follows:

First interim	Announced end of July and paid in October.
Second interim	Announced in February and paid in April.

TRADEMARKS

All products or brand names included in Note 3 of this Interim Statement and the following names are trademarks of, or licensed to, AstraZeneca PLC or its subsidiary companies:

Atacand HCT Atacand Plus Crestor Faslodex Iressa Prilosec Pulmicort Respules Rhinocort Aqua Toprol-XL Viozan Zomig Rapimelt Zomig ZMT

ADDRESSES FOR CORRESPONDENCE

Registrar and Transfer Office	Depository for ADRs	Registered Office	Swedish Securities Register Centre
The AstraZeneca Registrar Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA Tel: (01903) 502 541	Morgan Guaranty Trust Company of New York ADR Service Center PO Box 842006 Boston, MA 02284-2006 Tel: (781) 575 4328	15 Stanhope Gate London W1K 1LN Tel: (020) 7304 5000	Vardepapperscentralen VPC AB Box 7822 S-103 97 Stockholm Sweden Tel: (8) 402 9000

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability and the risks related to the difficulty of completing the integration of Astra's and Zeneca's large and complex businesses on a timely basis and realising synergies.